(Q33699351)

28 July 2017

1 reference

title

Therapy of relapsing multiple sclerosis. Treatment approaches for nonresponders (English)

1 reference

28 July 2017

Cohen JA

1

1 reference

28 July 2017

Carter JL

series ordinal

2

1 reference

28 July 2017

Kinkel RP

series ordinal

3

1 reference

28 July 2017

Schwid SR

series ordinal

4

1 reference

28 July 2017

1 July 1999

1 reference

Journal of Neuroimmunology

28 July 2017

1 reference

28 July 2017

98

1 reference

28 July 2017

1

1 reference

28 July 2017

29-36

1 reference

Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses.

28 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900078-8

7 January 2021

Long-term safety of azathioprine therapy in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900078-8

7 January 2021

Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900078-8

7 January 2021

Effect of steroids on Gd-enhancing lesions before and during recombinant beta interferon 1a treatment in relapsing remitting multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900078-8

7 January 2021

Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900078-8

7 January 2021

A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900078-8

7 January 2021

Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900078-8

7 January 2021

Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900078-8

7 January 2021

Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900078-8

7 January 2021

Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900078-8

7 January 2021

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900078-8

7 January 2021

Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900078-8

7 January 2021

Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900078-8

7 January 2021

High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900078-8

7 January 2021

Additive effects of copolymer-1 and interferon beta-1b on the immune response to myelin basic protein.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900078-8

7 January 2021

Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900078-8

7 January 2021

Copolymer-1-induced inhibition of antigen-specific T cell activation: interference with antigen presentation

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900078-8

7 January 2021

Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900078-8

7 January 2021

In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900078-8

7 January 2021

The measurement of ambulatory impairment in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900078-8

7 January 2021

Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900078-8

7 January 2021

Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900078-8

7 January 2021

Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900078-8

7 January 2021

Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900078-8

7 January 2021

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900078-8

7 January 2021

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900078-8

7 January 2021

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900078-8

7 January 2021

Overview of azathioprine treatment in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900078-8

7 January 2021

10.1016/S0165-5728(99)00078-8

Identifiers

DOI

1 reference

28 July 2017

1 reference